IBSSure SIBO

Description

IBS is a commonly occurring collection of symptoms diagnosed in the world of gastroenterology. It is the most common GI disorder with worldwide prevalence rates ranging from 10-15%. There are between 2.4 and 3.5 million physician visits annually for IBS in the US. Recent research has shown that up to 84% of those with an IBS diagnosis test positive for  Small Intestinal Bacterial Overgrowth. (SIBO Test)

Breath tests for Small Intestinal Bacterial Overgrowth (SIBO) can be very time consuming for patients, as well as inaccurate, due to many factors.
Glucose Breath Testing: 62% sensitivity / 81 % specific
Lactose Breath Testing: 52% sensitivity / 85 % specific

IBSSure^TM is a simple blood test that detects two antibodies which are indicative of bacterial-pathogen-induced motility dysfunction, which can lead to increased incidence of SIBO.
CdtB toxins (cytolethal distending toxin B) are released by gastroenteritis-causing bacteria, against which antibodies are produced by the immune system. These antibodies interact with a protein, vinculin, present in the intestinal cell-lining matrix. This interaction compromises and impairs digestive motility. This pathological breakdown of the gastrointestinal motility complex is foundational to chronic SIBO development and recurrence and has been well-studied and documented.

SIBO does not happen to only people with GI symptoms!

Illnesses that can be associated with SIBO:
Autoimmunity, Chronic Fatigue Syndrome, Ehler’s Danlos, H Pylori, Osteoporosis, Renal Failure, Malabsorption)